Flamenter Keratitli Kuru Göz Olgusunda Siklosporin A Tedavisi

Evsen, Sina; Arı, Şeyhmus
December 2011
Glokom-Katarakt/Journal of Glaucoma-Cataract;Dec2011, Vol. 6 Issue 4, p263
Academic Journal
Nowadays dry eye is a very common disease. Most of the patients examined in the ophtalmology clinics have dry eye complaints. Dry eye patients that can be classified as mild, moderate, severe relieve by artificial tear usage for a while. Nevertheless this treatment is not a permanent solution, also in some severe patients it is not sufficient alone. In our case 55 years old male patient was a severe dry eye patient who progressed to flamentary keratitis. Previously he used many topical treatments but had no benefit and disease progressed. Topical cyclosporine A together with artificial tear was used for the patient. Flamentary keratitis was regressed obviously and signs and symptoms of the patient were improved.


Related Articles

  • Cyclosporine mitigates dry eye symptoms over 2 years. Hasson, Matt // Ocular Surgery News Asia-Pacific;Apr2010, Vol. 21 Issue 4, p8 

    The article reports that switching from the use of topical cyclosporine to artificial tears can result in worse dry eye conditions. According to a study, patients who maintained cyclosporine treatment for a two-year period were found to have improvements in their dry eye symptoms. Cyclosporine...

  • Innovation improves dry eye therapies. DePaolis, Michael D. // Primary Care Optometry News;Nov2008, Vol. 13 Issue 11, p3 

    The article examines how innovations can improve dry eye therapies. It notes that inflammation adversely influences neural regulation and glandular secretion, compromising tear production and stability. The fundamentals of dry eye treatment which includes the use of omega 3s, lid hygiene and a...

  • Progression: The New Approach to Dry Eye. Rao, Sanjay N. // Review of Ophthalmology;Oct2008, Vol. 15 Issue 10, p55 

    The article offers information on dry-eye syndrome. International Dry Eye Workshop depicted dry eye as a multi-factorial disease of the tears and ocular surface resulting in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface....

  • Aprospective, multicenter, noninterventional study of Optive Plus® in the treatment of patients with dry eye: the prolipid study. Kaercher, Thomas; Thelen, Ulrich; Brief, Gerrett; Morgan-Warren, Robert J.; Leaback, Richard // Clinical Ophthalmology;2014, Vol. 8, p1147 

    Objective: The aim was to evaluate the efficacy of Optive Plus®, an artificial tear containing castor oil, in patients with dry eye, in a routine clinical setting. Methods: This was a prospective, noninterventional study of patients with dry eye who switched from a prior therapy or who were...

  • The Advancing Science of Artificial Tears. Karpecki, Paul // Review of Cornea & Contact Lenses;Jan2007, p40 

    The article looks at developments and technological advances in artificial tears. Newly developed artificial tears are designed to mimic the natural formulation and function of natural tears. One example is Optive launched by Allergan Inc. The product is the first tear that works on the surface...

  • How to best incorporate Restasis in treating dry eye syndrome. White, Darrell E. // Ocular Surgery News;10/25/2014, Vol. 32 Issue 20, p6 

    The article offers insights for ophthalmologists on how to use ophthalmic emulsion Restasis in treating patients with dry eye syndrome. It notes that challenges in Restasis usage involve patient selection, chance of clinical success, and long-term medication adherence. Patients who qualify for...

  • New dry eye therapy shows good results in phase 2 study.  // Primary Care Optometry News;Jun2011, Vol. 16 Issue 6, p19 

    The article reports on a study which found that a new dry eye therapy involving the investigational molecule SAR 1118 reduced corneal staining, increased tear production and improved ocular surface disease index quality of life scores.

  • Low-viscosity artificial tear targets mild dry eye. Nemec, John // Ophthalmology Times;6/1/2002, Vol. 27 Issue 11, p62 

    Presents information on the GenTeal Mild lubricant drops which provide artificial tears for patients suffering from mild symptoms of dry eye. Primary advantage of the product; Importance of the transient preservative; Risk for long-term dry eye.

  • Dry Eye Disease and EFAs. NORDLIE, AUDREY // Naturopathic Doctor News & Review;Oct2014, Vol. 10 Issue 10, p10 

    The article discusses the cause and treatment for the Dry Eye Disease (DED), a multifactorial disease of the tears and ocular surface also known as keratoconjunctivitis sicca. It mentions that the DED is stemming from Meibomian gland dysfunction and neurotrophic deficiency. Moreover, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics